Inverse regulation of bridging integrator 1 and BCR-ABL1 in chronic myeloid leukemia

Stefania Trino, Luciana de Luca, Vittorio Simeon, Ilaria Laurenzana, Annalisa Morano, Antonella Caivano, Francesco la Rocca, Giuseppe Pietrantuono, Gabriella Bianchino, Vitina Grieco, Elisabetta Signorino, Alberto Fragasso, Maria Teresa Bochicchio, Claudia Venturi, Gianantonio Rosti, Giovanni Martinelli, Luigi Del Vecchio, Daniela Cilloni, Pellegrino Musto

Research output: Contribution to journalArticle

Abstract

Endocytosis is the major regulator process of tyrosine kinase receptor (RTK) functional activities. Bridging integrator 1 (BIN1) is a key protein involved in RTK intracellular trafficking. Here, we report, by studying 34 patients with chronic myeloid leukemia (CML) at diagnosis, that BIN1 gene is downregulated in CML as compared to healthy controls, suggesting an altered endocytosis of RTKs. Rab interactor 1 (RIN1), an activator of BIN1, displayed a similar behavior. Treatment of 57 patients by tyrosine kinase inhibitors caused, along with BCR-ABL1 inactivation, an increase of BIN1 and RIN1 expression, potentially restoring endocytosis. There was a significant inverse correlation between BIN1-RIN1 and BCR-ABL1 expression. In vitro experiments on both CML and nontumorigenic cell lines treated with Imatinib confirmed these results. In order to provide another proof in favor of BIN1 and RIN1 endocytosis function in CML, we demonstrated that Imatinib induced, in K562 cell line, BIN1-RIN1 upregulation accompanied by a parallel AXL receptor internalization into cytoplasmic compartment. This study shows a novel deregulated mechanism in CML patients, indicating BIN1 and RIN1 as players in the maintenance of the abnormal RTK signaling in this hematological disease.

Original languageEnglish
JournalTumor Biology
DOIs
Publication statusAccepted/In press - Jul 21 2015

Fingerprint

Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Endocytosis
Cell Line
K562 Cells
Hematologic Diseases
Receptor Protein-Tyrosine Kinases
Protein-Tyrosine Kinases
Up-Regulation
Down-Regulation
Maintenance
Genes
Proteins
Imatinib Mesylate
Therapeutics

Keywords

  • AXL
  • BCR-ABL1
  • Bridging integrator 1
  • Chronic myeloid leukemia
  • Rab interactor 1

ASJC Scopus subject areas

  • Cancer Research

Cite this

Trino, S., de Luca, L., Simeon, V., Laurenzana, I., Morano, A., Caivano, A., ... Musto, P. (Accepted/In press). Inverse regulation of bridging integrator 1 and BCR-ABL1 in chronic myeloid leukemia. Tumor Biology. https://doi.org/10.1007/s13277-015-3772-9

Inverse regulation of bridging integrator 1 and BCR-ABL1 in chronic myeloid leukemia. / Trino, Stefania; de Luca, Luciana; Simeon, Vittorio; Laurenzana, Ilaria; Morano, Annalisa; Caivano, Antonella; la Rocca, Francesco; Pietrantuono, Giuseppe; Bianchino, Gabriella; Grieco, Vitina; Signorino, Elisabetta; Fragasso, Alberto; Bochicchio, Maria Teresa; Venturi, Claudia; Rosti, Gianantonio; Martinelli, Giovanni; Del Vecchio, Luigi; Cilloni, Daniela; Musto, Pellegrino.

In: Tumor Biology, 21.07.2015.

Research output: Contribution to journalArticle

Trino, S, de Luca, L, Simeon, V, Laurenzana, I, Morano, A, Caivano, A, la Rocca, F, Pietrantuono, G, Bianchino, G, Grieco, V, Signorino, E, Fragasso, A, Bochicchio, MT, Venturi, C, Rosti, G, Martinelli, G, Del Vecchio, L, Cilloni, D & Musto, P 2015, 'Inverse regulation of bridging integrator 1 and BCR-ABL1 in chronic myeloid leukemia', Tumor Biology. https://doi.org/10.1007/s13277-015-3772-9
Trino, Stefania ; de Luca, Luciana ; Simeon, Vittorio ; Laurenzana, Ilaria ; Morano, Annalisa ; Caivano, Antonella ; la Rocca, Francesco ; Pietrantuono, Giuseppe ; Bianchino, Gabriella ; Grieco, Vitina ; Signorino, Elisabetta ; Fragasso, Alberto ; Bochicchio, Maria Teresa ; Venturi, Claudia ; Rosti, Gianantonio ; Martinelli, Giovanni ; Del Vecchio, Luigi ; Cilloni, Daniela ; Musto, Pellegrino. / Inverse regulation of bridging integrator 1 and BCR-ABL1 in chronic myeloid leukemia. In: Tumor Biology. 2015.
@article{59fcfe5f5fde4bfbb2c22c20e4153857,
title = "Inverse regulation of bridging integrator 1 and BCR-ABL1 in chronic myeloid leukemia",
abstract = "Endocytosis is the major regulator process of tyrosine kinase receptor (RTK) functional activities. Bridging integrator 1 (BIN1) is a key protein involved in RTK intracellular trafficking. Here, we report, by studying 34 patients with chronic myeloid leukemia (CML) at diagnosis, that BIN1 gene is downregulated in CML as compared to healthy controls, suggesting an altered endocytosis of RTKs. Rab interactor 1 (RIN1), an activator of BIN1, displayed a similar behavior. Treatment of 57 patients by tyrosine kinase inhibitors caused, along with BCR-ABL1 inactivation, an increase of BIN1 and RIN1 expression, potentially restoring endocytosis. There was a significant inverse correlation between BIN1-RIN1 and BCR-ABL1 expression. In vitro experiments on both CML and nontumorigenic cell lines treated with Imatinib confirmed these results. In order to provide another proof in favor of BIN1 and RIN1 endocytosis function in CML, we demonstrated that Imatinib induced, in K562 cell line, BIN1-RIN1 upregulation accompanied by a parallel AXL receptor internalization into cytoplasmic compartment. This study shows a novel deregulated mechanism in CML patients, indicating BIN1 and RIN1 as players in the maintenance of the abnormal RTK signaling in this hematological disease.",
keywords = "AXL, BCR-ABL1, Bridging integrator 1, Chronic myeloid leukemia, Rab interactor 1",
author = "Stefania Trino and {de Luca}, Luciana and Vittorio Simeon and Ilaria Laurenzana and Annalisa Morano and Antonella Caivano and {la Rocca}, Francesco and Giuseppe Pietrantuono and Gabriella Bianchino and Vitina Grieco and Elisabetta Signorino and Alberto Fragasso and Bochicchio, {Maria Teresa} and Claudia Venturi and Gianantonio Rosti and Giovanni Martinelli and {Del Vecchio}, Luigi and Daniela Cilloni and Pellegrino Musto",
year = "2015",
month = "7",
day = "21",
doi = "10.1007/s13277-015-3772-9",
language = "English",
journal = "Tumor Biology",
issn = "1010-4283",
publisher = "Springer Netherlands",

}

TY - JOUR

T1 - Inverse regulation of bridging integrator 1 and BCR-ABL1 in chronic myeloid leukemia

AU - Trino, Stefania

AU - de Luca, Luciana

AU - Simeon, Vittorio

AU - Laurenzana, Ilaria

AU - Morano, Annalisa

AU - Caivano, Antonella

AU - la Rocca, Francesco

AU - Pietrantuono, Giuseppe

AU - Bianchino, Gabriella

AU - Grieco, Vitina

AU - Signorino, Elisabetta

AU - Fragasso, Alberto

AU - Bochicchio, Maria Teresa

AU - Venturi, Claudia

AU - Rosti, Gianantonio

AU - Martinelli, Giovanni

AU - Del Vecchio, Luigi

AU - Cilloni, Daniela

AU - Musto, Pellegrino

PY - 2015/7/21

Y1 - 2015/7/21

N2 - Endocytosis is the major regulator process of tyrosine kinase receptor (RTK) functional activities. Bridging integrator 1 (BIN1) is a key protein involved in RTK intracellular trafficking. Here, we report, by studying 34 patients with chronic myeloid leukemia (CML) at diagnosis, that BIN1 gene is downregulated in CML as compared to healthy controls, suggesting an altered endocytosis of RTKs. Rab interactor 1 (RIN1), an activator of BIN1, displayed a similar behavior. Treatment of 57 patients by tyrosine kinase inhibitors caused, along with BCR-ABL1 inactivation, an increase of BIN1 and RIN1 expression, potentially restoring endocytosis. There was a significant inverse correlation between BIN1-RIN1 and BCR-ABL1 expression. In vitro experiments on both CML and nontumorigenic cell lines treated with Imatinib confirmed these results. In order to provide another proof in favor of BIN1 and RIN1 endocytosis function in CML, we demonstrated that Imatinib induced, in K562 cell line, BIN1-RIN1 upregulation accompanied by a parallel AXL receptor internalization into cytoplasmic compartment. This study shows a novel deregulated mechanism in CML patients, indicating BIN1 and RIN1 as players in the maintenance of the abnormal RTK signaling in this hematological disease.

AB - Endocytosis is the major regulator process of tyrosine kinase receptor (RTK) functional activities. Bridging integrator 1 (BIN1) is a key protein involved in RTK intracellular trafficking. Here, we report, by studying 34 patients with chronic myeloid leukemia (CML) at diagnosis, that BIN1 gene is downregulated in CML as compared to healthy controls, suggesting an altered endocytosis of RTKs. Rab interactor 1 (RIN1), an activator of BIN1, displayed a similar behavior. Treatment of 57 patients by tyrosine kinase inhibitors caused, along with BCR-ABL1 inactivation, an increase of BIN1 and RIN1 expression, potentially restoring endocytosis. There was a significant inverse correlation between BIN1-RIN1 and BCR-ABL1 expression. In vitro experiments on both CML and nontumorigenic cell lines treated with Imatinib confirmed these results. In order to provide another proof in favor of BIN1 and RIN1 endocytosis function in CML, we demonstrated that Imatinib induced, in K562 cell line, BIN1-RIN1 upregulation accompanied by a parallel AXL receptor internalization into cytoplasmic compartment. This study shows a novel deregulated mechanism in CML patients, indicating BIN1 and RIN1 as players in the maintenance of the abnormal RTK signaling in this hematological disease.

KW - AXL

KW - BCR-ABL1

KW - Bridging integrator 1

KW - Chronic myeloid leukemia

KW - Rab interactor 1

UR - http://www.scopus.com/inward/record.url?scp=84937611500&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84937611500&partnerID=8YFLogxK

U2 - 10.1007/s13277-015-3772-9

DO - 10.1007/s13277-015-3772-9

M3 - Article

AN - SCOPUS:84937611500

JO - Tumor Biology

JF - Tumor Biology

SN - 1010-4283

ER -